HOME >> MEDICINE >> NEWS
The hunt for a hepatitis C vaccine is under way at Saint Louis University School of Medicine

ST. LOUIS Human clinical trials involving investigational vaccines to prevent Hepatitis C are rare. In the fall of 2003 there was a first-ever study at Saint Louis University Center for Vaccine Development, and an earlier small study at Johns Hopkins School of Medicine.

Now a new trial -- much larger than these two earlier studies -- is about to start at Saint Louis University. Two hundred volunteers are needed, and SLU is the only site in the United States conducting this study.

"Sixteen years ago, the hepatitis C virus had not even been identified and now there are an estimated 170 million people around the world infected." said Sharon Frey, M.D., professor of internal medicine in the division of infectious disease at Saint Louis University School of Medicine. "It is critical that we develop a vaccine to combat this growing health problem."

The purpose of this research is to study the safety and effectiveness of the Chiron Corp.'s investigational hepatitis vaccine. Although the Chiron vaccine has been given to people in previous studies, this is the first time the vaccine will be tested in humans with a different "adjuvant." (A vaccine adjuvant is a chemical designed to help the body make a better response to vaccines.) Volunteers will be randomly assigned to receive one of the nine different combinations of hepatitis C virus vaccine and adjuvant.

"Officials at the Centers for Disease Control and Prevention believe that approximately 40,000 new cases of hepatitis C infections occur every year," Frey said, "therefore a vaccine to prevent the infection would be an important breakthrough in controlling the spread of the hepatitis C virus."

The study is being conducted by Saint Louis University's Center for Vaccine Development (led by the division of infectious diseases and immunology) in collaboration with Saint Louis University Liver Center (led by the school's division of gastroenterology and hepatology). This research
'"/>

Contact: Joseph Muehlenkamp
muehlenk@slu.edu
314-977-8015
Saint Louis University
3-May-2006


Page: 1 2

Related medicine news :

1. UK and other European countries should introduce universal childhood hepatitis B vaccination
2. Liver cancer patients with high serum levels of hepatitis B virus face poorer outcomes
3. Cure for hepatitis C announced by VCU researcher
4. The hepatitis C link: Diagnose, treat, transplant
5. Could statins be a new option for hepatitis C patients?
6. Risk of lymphoma increases with hepatitis C virus infection
7. Outcomes for patients with hepatitis B who need liver transplants
8. Interferon-treated hepatitis C patients likely to experience retinopathy
9. Racial differences seen in steatosis in patients with hepatitis C
10. MGH study examines impact of infection with both HIV and hepatitis C virus
11. Making headway against hepatitis C: SLU study shows new drug combo effective in nonresponders

Post Your Comments:
(Date:3/4/2015)... San Jose, CA (PRWEB) March 04, 2015 ... products produced by companies whose management forgot – or ... assessing potential value: Validate the market based on physician ... “We've seen companies – more specifically, founders – become ... to answer the key question: Will physicians use the ...
(Date:3/3/2015)... As payers pledge to move the bulk ... next few years, they are testing various initiatives to ... care spending they control — involved. The March issue ... tracks some of the strategies proposed by industry ... organization (ACO)-type model. , One way to get specialists ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 NOVAtime ... of enterprise Time and Attendance / Workforce Management ... to NOVAtime SaaS Workforce Management / Time ... and attendance processes. , Since 2004, Innovative ... developmental disabilities with the best quality of life. ...
(Date:3/3/2015)... Loma Linda University Health announced today, that ... it will be offering new, healthier choices in all ... the past year, a cross-section of Loma Linda University ... listening to vendors, sampling their products, and ultimately recommending ... Most recently, a food fair was held during which ...
(Date:3/3/2015)... Sacramento, CA (PRWEB) March 03, 2015 ... cancers. , Researchers at UC Davis have developed and ... of cancer cells, causing them to self-destruct. This novel ... – responsible for a usually fatal type of brain ... aggressive cancers. , The article, to be published ...
Breaking Medicine News(10 mins):Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 2Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 3Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 2Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 3Health News:Loma Linda University Health Rejuvenates Its Vending Machines with Healthier Selections 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4
(Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, ... stem cell-derived islet replacement therapy for the treatment of ... Dr. Eugene Brandon , Director of Strategic Relations ... annual summit showcases the latest in type 1 diabetes ... presentation are as follows: , , , ...
(Date:3/3/2015)... MOUNTAIN VIEW, Calif. , March 3, 2015 ... the enhanced drug discovery market, Frost & Sullivan ... Frost & Sullivan Award for Technology Leadership. Neopeutics ... offering clients a robust, cost-effective, and easily adaptable ... on agents that are catalogued as failing compounds ...
(Date:3/3/2015)... Colo. , March 3, 2015  Cannabis Science, ... development of cannabis-based medicine, today announced two important developments: ... its multiple global product launches, and CEO Raymond ... the Chicago HR Examiner. In the article, ... about leading a company in an industry that ...
Breaking Medicine Technology:ViaCyte to Present at JDRF TypeOneNation Research Summit 2Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 2Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 3Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 4Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 5CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 2CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 3CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 4CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 5
Cached News: